Immunohistochemistry ATM phospho Rabbit IgG Human

- Found 4932 results

Get tips on using Anti-Human CD282 (TLR2) FITC to perform Flowcytometry TLR2 (CD282) - Mouse / IgG1, kappa Human FITC

Products eBioscience Anti-Human CD282 (TLR2) FITC

Get tips on using Anti-Human CD3 PE-Cyanine7 to perform Flowcytometry CD3 - Mouse / IgG1, kappa Human PE-Cyanine7

Products eBioscience Anti-Human CD3 PE-Cyanine7

Get tips on using Anti-Human CD56 (NCAM) APC-eFluor® 780 to perform Flowcytometry CD56 (NCAM) - Mouse / IgG1, kappa Human APC-eFluor 780

Products eBioscience Anti-Human CD56 (NCAM) APC-eFluor® 780

miRNA is the inherent gene silencing machinery which can have more than one mRNA target, whereas siRNA can be designed to target a particular mRNA target. By design, both siRNA and miRNA are 20-25 nucleotides in length. The target sequence for siRNAs is usually located within the open reading frame, between 50 and 100 nucleotides downstream of the start codon. There are two ways in which cells can be transfected with desired RNAi: 1. Direct transfection (with calcium phosphate co-precipitation or cationic lipid mediated transfection using lipofectamine or oligofectamine), and 2. Making RNAi lentiviral constructs (followed by transformation and transduction). Lentiviral constructs are time consuming, but provide a more permanent expression of RNAi in the cells, and consistent gene silencing. Direct transfection of oligonucleotides provides temporary genetic suppression. Traditional methods like calcium phosphate co-precipitation have challenges like low efficiency, poor reproducibility and cell toxicity. Whereas, cationic lipid-based transfection reagents are able to overcome these challenges, along with applicability to a large variety of eukaryotic cell lines. When using oligos, the ideal concentration lies between 10-50nM for effective transfection.

RNA siRNA / miRNA gene silencing Human Primary Human Hepatocytes CYP3A4

miRNA is the inherent gene silencing machinery which can have more than one mRNA target, whereas siRNA can be designed to target a particular mRNA target. By design, both siRNA and miRNA are 20-25 nucleotides in length. The target sequence for siRNAs is usually located within the open reading frame, between 50 and 100 nucleotides downstream of the start codon. There are two ways in which cells can be transfected with desired RNAi: 1. Direct transfection (with calcium phosphate co-precipitation or cationic lipid mediated transfection using lipofectamine or oligofectamine), and 2. Making RNAi lentiviral constructs (followed by transformation and transduction). Lentiviral constructs are time consuming, but provide a more permanent expression of RNAi in the cells, and consistent gene silencing. Direct transfection of oligonucleotides provides temporary genetic suppression. Traditional methods like calcium phosphate co-precipitation have challenges like low efficiency, poor reproducibility and cell toxicity. Whereas, cationic lipid-based transfection reagents are able to overcome these challenges, along with applicability to a large variety of eukaryotic cell lines. When using oligos, the ideal concentration lies between 10-50nM for effective transfection.

RNA siRNA / miRNA gene silencing Human Primary Human Hepatocytes CYP2B6

Get tips on using Leukocyte Alkaline Phosphatase Kit to perform Acid phosphatase assay cell type - human periodontal ligament cells

Products Sigma-Aldrich Leukocyte Alkaline Phosphatase Kit

Get tips on using BrdU antibody to perform Immunohistochemistry Mouse - BrdU

Products Bio-Rad Laboratories BrdU antibody

Get tips on using LC3B Antibody to perform Immunohistochemistry Mouse - LC3

Products Novus Biologicals LC3B Antibody

Get tips on using LC3B Antibody to perform Immunohistochemistry Mouse - LC3

Products Novus Biologicals LC3B Antibody
T-4103 Product

Get tips on using T-4103 to perform Immunohistochemistry Mouse - Somatostatin

Products BMA Biomedicals T-4103

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms